Arterez
Business Services · United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.arterez.comRevenue
<$5 MillionIndustry
About Arterez
Arterez, Inc. is a Michigan-based biotechnology company focused on developing innovative diagnostics and therapeutics for cardiovascular disease (CVD), the leading chronic disease globally. Their unique platform targets the multifactorial root causes of CVD through proprietary combo therapies and multi-marker diagnostics. The company's lead product, Embotricin, is an oral therapy designed to prevent and reverse arterial plaques, while their GlycoCardia technology offers a comprehensive diagnostic approach to monitor disease progression. Arterez aims to revolutionize the treatment of CVD by addressing upstream disease etiology rather than merely alleviating symptoms.Explore more
Arterez Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Arterez
Compare insights from companies similar to Arterez, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Arterez Tech Stack
A closer look at the technologies used by Arterez
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Arterez
Sign Up For FreeTo access detailed company insights
Arterez, Inc. is a Michigan-based biotechnology company focused on developing innovative diagnostics and therapeutics for cardiovascular disease (CVD), the leading chronic disease globally. Their unique platform targets the multifactorial root causes of CVD through proprietary combo therapies and multi-marker diagnostics. The company's lead product... Read More
